Form 4: Ionis Pharmaceuticals Executive C. Frank Bennett Acquires Additional Shares Through Employee Stock Purchase Plan

EVP, Chief Scientific Officer of Ionis Pharmaceuticals, C. Frank Bennett, reports acquiring 177 shares of common stock through the company's employee stock purchase plan.

Summary

• On August 30, 2024, C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, acquired 177 shares of common stock through the company's Amended and Restated 2000 Employee Stock Purchase Plan.
• The shares were purchased at a price of $38.641 per share.
• Following the transaction, Bennett directly owns 79,607 shares of Ionis Pharmaceuticals common stock.
• These shares may not be sold until February 28, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The purchase of shares by an executive is generally seen as a positive sign, indicating confidence in the company's prospects. However, it's a routine transaction under an existing plan.

Positives

• The acquisition of shares by a high-ranking executive could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Executive stock purchases are common and are usually viewed as a positive sign, indicating the executive's belief in the company's future performance.

Key Dates